TSLA
特斯拉
-- 435.940 NVDA
英伟达
-- 133.920 PLTR
Palantir
-- 78.880 AMD
美国超微公司
-- 119.730 QUBT
Quantum Computing
-- 16.805 
资讯
Barinthus Bio已完成慢性乙型肝炎HBV003临床试验的2亿阶段招募，并进行前列腺癌PCA001临床试验的1期。
• VTP-300作为潜在的慢性乙型肝炎功能性治愈方案的一部分正在接受评估。
• HBV003的中期数据更新预计在2024年第四季度公布。
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide t cells to control disease, announced the completion of enrollment for two clinical trials: HBV003, a Phase 20亿 clinical trial of VTP-300 in adults with chronic hepatitis b (CHB); and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen (PSA) after definitive local therapy for prostate cancer (i.e., biochemical recurrence).
• HBV003的中期数据更新预计在2024年第四季度公布。
• Data update for PCA001 anticipated in H1 2025.
OXFORD, United Kingdom, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide t cells to control disease, announced the completion of enrollment for two clinical trials: HBV003, a Phase 20亿 clinical trial of VTP-300 in adults with chronic hepatitis b (CHB); and PCA001, a Phase 1 clinical trial of VTP-850 in men with rising prostate-specific antigen (PSA) after definitive local therapy for prostate cancer (i.e., biochemical recurrence).
免责声明：社区由Moomoo Technologies Inc.提供，仅用于教育目的。
更多信息
评论
登录发表评论